Concordia Healthcare Corp. (NASDAQ:CXRX) shares were down 1.4% on Friday . The company traded as low as $8.14 and last traded at $8.31, with a volume of 652,131 shares trading hands. The stock had previously closed at $8.43.

A number of research analysts have weighed in on CXRX shares. RBC Capital Markets reiterated an “outperform” rating and set a $33.00 price objective on shares of Concordia Healthcare Corp. in a research report on Monday, August 15th. TD Securities reiterated a “buy” rating and set a $37.00 price objective (down previously from $45.00) on shares of Concordia Healthcare Corp. in a research report on Wednesday, June 29th. CIBC cut shares of Concordia Healthcare Corp. from a “sector perform” rating to an “underperform” rating and set a $7.80 price target on the stock. in a report on Monday, August 15th. Zacks Investment Research cut shares of Concordia Healthcare Corp. from a “buy” rating to a “hold” rating in a report on Monday, July 18th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $73.00 price target on shares of Concordia Healthcare Corp. in a report on Tuesday, June 21st. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $39.87.

The company’s 50 day moving average is $13.96 and its 200-day moving average is $23.53. The stock’s market capitalization is $417.32 million.

Concordia Healthcare Corp. (NASDAQ:CXRX) last posted its quarterly earnings results on Friday, August 12th. The company reported $1.38 EPS for the quarter, hitting the consensus estimate of $1.38. The company had revenue of $231.70 million for the quarter, compared to analysts’ expectations of $229.76 million. The company’s revenue was up 208.1% on a year-over-year basis. On average, equities research analysts predict that Concordia Healthcare Corp. will post $5.37 EPS for the current year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.